# Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B

> **NCT07282249** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Grand Theravac Life Sciences (Nanjing) Co., Ltd.** · enrollment: 630 (estimated)

## Conditions studied

- Chronic hepatitisB

## Interventions

- **DRUG:** TVAV-008
- **DRUG:** PegIFNα2b
- **DRUG:** Placeb

## Key facts

- **NCT ID:** NCT07282249
- **Lead sponsor:** Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 630 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282249, "Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07282249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*